Bayer entered an exclusive global licensing and collaboration agreement with Kumquat Biosciences to develop and commercialize a KRAS G12D inhibitor, potentially worth over $1.3 billion. Kumquat recently secured FDA clearance for the investigational new drug (IND) application to start phase 1 trials. KRAS G12D is the most common oncogenic KRAS mutation without approved targeted therapies, prevalent in pancreatic, colorectal, and lung cancers. Bayer aims to bolster its precision oncology portfolio with this asset, joining other developers targeting KRAS variants. The deal includes upfront, milestones, and royalties, with Bayer assuming future development and commercialization.